- Home
- CGTX vs LRE Comparison
CGTX vs LRE Comparison
Compare CGTX & LRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGTX
- LRE
- Stock Information
- Founded
- CGTX 2007
- LRE 2001
- Country
- CGTX United States
- LRE Japan
- Employees
- CGTX N/A
- LRE N/A
- Industry
- CGTX Biotechnology: Pharmaceutical Preparations
- LRE
- Sector
- CGTX Health Care
- LRE
- Exchange
- CGTX Nasdaq
- LRE Nasdaq
- Market Cap
- CGTX 20.5M
- LRE 17.6M
- IPO Year
- CGTX 2021
- LRE 2023
- Fundamental
- Price
- CGTX $0.26
- LRE $1.81
- Analyst Decision
- CGTX Strong Buy
- LRE
- Analyst Count
- CGTX 5
- LRE 0
- Target Price
- CGTX $5.63
- LRE N/A
- AVG Volume (30 Days)
- CGTX 1.8M
- LRE 19.6K
- Earning Date
- CGTX 08-07-2025
- LRE 01-01-0001
- Dividend Yield
- CGTX N/A
- LRE N/A
- EPS Growth
- CGTX N/A
- LRE N/A
- EPS
- CGTX N/A
- LRE 0.29
- Revenue
- CGTX N/A
- LRE $117,804,154.00
- Revenue This Year
- CGTX N/A
- LRE N/A
- Revenue Next Year
- CGTX N/A
- LRE N/A
- P/E Ratio
- CGTX N/A
- LRE $5.76
- Revenue Growth
- CGTX N/A
- LRE 8.82
- 52 Week Low
- CGTX $0.22
- LRE $1.10
- 52 Week High
- CGTX $2.54
- LRE $13.76
- Technical
- Relative Strength Index (RSI)
- CGTX 37.68
- LRE 62.44
- Support Level
- CGTX $0.29
- LRE $1.64
- Resistance Level
- CGTX $0.32
- LRE $1.84
- Average True Range (ATR)
- CGTX 0.03
- LRE 0.16
- MACD
- CGTX 0.00
- LRE -0.02
- Stochastic Oscillator
- CGTX 12.50
- LRE 29.58
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.